Dupont to Head Research and Development at Atara Biotherapeutics
15 May 2020 - - US-based T-cell immunotherapies developer Atara Biotherapeutics, Inc. (NASDAQ: ATRA) has named cell therapy and oncology expert Jakob Dupont, M.D. as executive vice president, global head of research and development, the company said.

Dupont joins Atara from Gossamer Bio where he served as the Chief Medical officer overseeing global development, regulatory and quality activities for the company, advancing therapeutics in the disease areas of immunology, inflammation and oncology.

Prior to that, he served as vice president and Global Head of Breast and Gynecologic Cancer Development for Genentech/Roche, where he was responsible for the global development of Herceptin, Perjeta, Kadcyla, ipatesetib, taselisib, and Tecentriq, among others, and co-led the Genentech/Roche Breast Cancer Disease Area Strategy Team and served on the Oncology Leadership Team.

He and his team secured a number of regulatory approvals including Perjeta and Kadcyla in adjuvant HER2+ breast cancer and Tecentriq for triple negative breast cancer.

Prior to his recent role at Genentech/Roche, Dr. Dupont was chief medical officer and senior vice president of OncoMed Pharmaceuticals, Inc. where he oversaw the successful submissions of eight investigational new drug applications and 26 clinical trial initiations and also participated in the execution of major corporate initiatives, including OncoMed's initial public offering and a partnership agreement with Celgene.

Dupont began his career in the biotech industry with Genentech/Roche where he served as Global Medical director of Avastin and was Group director for Avastin development, overseeing the early angiogenesis pipeline.

Dupont played a key role in the development and approval of Avastin in ovarian, cervical and breast cancers.

Prior to first joining Genentech/Roche in 2006, Dr. Dupont was a faculty member and laboratory researcher at Memorial Sloan Kettering Cancer Center and oversaw a Phase 1 solid tumor and GYN oncology clinic and a tumor immunology laboratory.

During his time at MSK, Dr. Dupont worked in cell therapy research in the Laboratory of Bone Marrow Transplantation led by Richard O'Reilly, M.D., a leader in the field of allogeneic T-cell therapy and the scientific inventor of tab-cel, and was a research fellow in the Laboratory of Gene Transfer and Gene Expression led by Michel Sadelain, M.D., Ph.D, a world renowned immunologist and pioneer in the field of CAR-T therapy and Atara's collaborator on multiple next generation CAR-T programs.

Dupont has received numerous grants and awards and has co-authored 47 peer-reviewed publications, has 30 patents and has also served as adjunct clinical faculty in medical oncology at Stanford University, overseeing a GYN Oncology clinic.

Atara Biotherapeutics is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease.